Agenus to Present BOT/BAL Advancements and Future Outlook in Virtual Briefing on August 27, 2025

Agenus to host virtual Stakeholder Briefing on August 27, 2025, covering strategic advancements and future outlook in immuno-oncology. Key presentations will include updates on botensilimab and balstilimab programs and their impact on colorectal cancer studies. The event will also cover the Phase 3 BATTMAN study in metastatic CRC and conclude with a live Q&A session.

Agenus Inc. (Nasdaq: AGEN), a leading immuno-oncology company, will host a virtual Stakeholder Briefing on August 27, 2025, at 4:00 p.m. ET. The event aims to provide insights into transformative developments that could shape the future of cancer treatment. Key presentations will cover strategic advancements, financial overviews, and milestones in the company's pipeline, with a particular focus on colorectal cancer (CRC) studies.

The briefing will feature presentations from senior management and industry thought leaders, including Garo H. Armen, PhD, Founder, Chairman, and CEO of Agenus; Jennifer Buell, PhD, CEO of MiNK Therapeutics and Chair of the Executive Committee of Agenus; and Richard M. Goldberg, MD, Chief Development Officer of Agenus. Additionally, experts in gastrointestinal oncology and tumor immune evasion will share their insights. The event will also include updates on the Phase 3 BATTMAN study in metastatic CRC.

The agenda will include a strategic and financial overview, achievements tied to the Zydus partnership closing, patient needs fueling interest in CRC studies, recent data from the botensilimab (BOT) and balstilimab (BAL) program, and an overview of the Phase 3 BATTMAN study in metastatic CRC. The session will conclude with a live Q&A.

About Agenus and its Programs

Agenus is a leading immuno-oncology company with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches. Agenus has robust end-to-end development capabilities across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint.

Botensilimab (BOT) and Balstilimab (BAL)

Botensilimab is a multifunctional, human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. It has shown clinical responses across nine metastatic, late-line cancers and has been evaluated in approximately 1,200 patients across phase 1 and phase 2 clinical trials [1].

Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. It has been evaluated in 900 patients and has demonstrated clinical activity and a favorable tolerability profile in several tumor types [1].

Forward-Looking Statements

The briefing will include forward-looking statements, which are subject to risks and uncertainties that could cause actual results to differ materially from current expectations. Factors that could cause actual results to differ include, but are not limited to, those described under the "Risk Factors" section of Agenus' most recent Annual Report on Form 10-K for 2024 and subsequent Quarterly Reports on Form 10-Q filed with the SEC [1].

Stakeholder Briefing Details

The virtual event will be accessible via webcast and conference call. Interested parties can register for the webcast at [Webcast Link](https://events.q4inc.com/attendee/965806302) and for the audience conference call at [Audience Conference Call Registration Link](https://registrations.events/direct/Q4I7324292). The conference ID is 73242.

References

[1] https://investor.agenusbio.com/news/news-details/2025/Agenus-to-Unveil-BOTBAL-Strategic-Advancements-Key-Milestones-and-Future-Outlook-in-Virtual-Stakeholder-Briefing-on-August-27-2025/default.aspx
[2] https://www.biospace.com/press-releases/agenus-to-unveil-bot-bal-strategic-advancements-key-milestones-and-future-outlook-in-virtual-stakeholder-briefing-on-august-27-2025